The Texas A&M University System today announced that it will seek to establish a National Center for Innovation in Advanced Development and Manufacturing. The purpose of the Center will be to develop medical countermeasures and ensure domestic vaccine manufacturing surge capacity for emerging infectious diseases, pandemic influenza and other threats during public health emergencies utilizing flexible, multiproduct technologies.
The Center will also provide research, education and workforce development programs for students entering diverse careers related to vaccine and medical countermeasure development, manufacturing, testing and approval. The A&M System effort is in direct response to a U.S. Department of Health and Human Services request for proposals published on March 30, 2011.
The A&M System is in discussion with strategic partners including world-class academic, commercial and non-profit institutions to contribute to the proposed Center. The A&M System’s potential team includes:
• Bavarian Nordic (Copenhagen, Denmark)
• Baylor College of Medicine (Houston, Texas)
• Blinn College (Brenham and Bryan, Texas)
• Caliber Biotherapeutics, LLC (Bryan/College Station, Texas)
• deltaDOT Ltd. (London, United Kingdom)
• GlaxoSmithKline Biologicals (Rixensart, Belgium)
• Kalon Biotherapeutics (College Station, Texas)
• Lovelace Respiratory Research Institute (Albuquerque, New Mexico)
• Mary Crowley Research Center (Dallas and Bryan, Texas)
• PPD, Inc. (Wilmington, North Carolina)
• Sartorius (Goettingen, Germany)
• The Sabin Vaccine Institute (Washington, D.C.)
• Texas A&M Institute for Preclinical Studies (College Station, Texas)
• Texas A&M University (College Station, Texas)
• Texas Biomedical Research Institute (formerly Southwest Foundation for Biomedical Research) (San Antonio, Texas)
• Texas Children’s Hospital (Houston, Texas)
• Texas Engineering Experiment Station (College Station, Texas)
• Texas Engineering Extension Service (College Station, Texas)
• Texas Veterinary Medical Diagnostic Laboratory (College Station, Texas)
• University of Texas Medical Branch at Galveston – Galveston National Laboratory (Galveston, Texas)
Additional team members will be announced in the coming weeks.
“This team represents some of the world’s finest scientists, engineers, corporations, and educators in the field. I believe that this distinguished group offers the best opportunity for our country, and indeed the globe, to achieve security against pandemics and bioterror threats, and in the process, significantly improve global health,” said Dr. Brett Giroir, vice chancellor for strategic initiatives at the A&M System and project director.